Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: enfortumab vedotin, ladiratuzumab vedotin, larotaxel +82 | 1.00 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 2 Parkinson's papers of 266 | 0.85 |
| pathways Reactome | Reactome did not answer (Reactome: The operation was aborted due to timeout) | 0.00 |
No case: the score is under the bar. Receipt 4304
Sealed predictions
- TUBA1A in dopamine neurons, braak+0.08 (p 0.838) → +0.34 (p 0.374)receipt 4312
Swarm cases
receipt 4312: TUBA1A in dopamine neurons, braak
- power
- full sample +0.22 (p 0.374, n 18), 95% CI -0.27 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.20 (p 0.418, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.26 (p 0.298, n 18). could be the mix.
- skeptic
- leave-one-out range +0.15 to +0.41, sign flips 0; without severely affected donors +0.22 (p 0.374, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TUBA1A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts